You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Syracuse, New York 13210

  • Hypocalcemia


This study will evaluate the impact of investigator and patient education and educational materials to foster calcium and vitamin D supplementation to mitigate the potential for hypocalcemia post Reclast® administration in patients with Paget's disease of bone.


Inclusion Criteria: - Written informed consent - As per currently approved Reclast® Package Insert: Exclusion Criteria: - As per currently approved Reclast® Package Insert:

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D

Official Title:

Post US Approval Voluntary Registry Study to Determine Incidence of Hypocalcemia Post Reclast® Treatment in Patients With Paget's Disease After Institution of Educational Strategies to Improve Adherence to Calcium and Vitamin D Supplementation

Overall Status:


Study Phase:

Phase 4



Minimum Age:


Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:


Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Non-Randomized, Endpoint Classificati

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals

Study Dates

Start Date:May 2008
Completion Date:November 2012
Completion Type:Actual
Primary Completion Date:November 2012
Primary Completion Type:Actual
Verification Date:February 2013
Last Changed Date:February 8, 2013
First Received Date:April 22, 2008

Study Outcomes

Outcome Type:Primary Outcome
Measure:Incidence of unresolved and resolved hypocalcemic events based on serum calcium measurements.
Time Frame:at days 9 - 11 post-infusion and, if needed, day 30, compared to baseline values and to historical c
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:Identify the incidence of symptoms associated with hypocalcemia based on responses to questionnaires.
Time Frame:at days 9 - 11 post-infusion and, if needed, day 30, compared to baseline
Safety Issues:True

Study Interventions

Intervention Type:Drug
Description:5mg i.v. annually ("real-life, physican prescribed")
Arm Name:Single arm
Other Name:zoledronic acid, Aclasta®

Study Arms

Study Arm Type:Other
Arm Name:Single arm
Description:Open label, single arm treatment study

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Novartis Pharmaceuticals

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.